Acrobiosystems 百普赛斯
14 significant filings since 1 Jun 2026: 7 on buyback, 6 on equity incentive and 1 on dividend. The latest, on 1 Sep 2026: 关于回购公司股份的进展公告.
自 1 Jun 2026 起有 14 份重大公告：buyback 7 份、equity incentive 6 份、dividend 1 份。最新一份（1 Sep 2026）：关于回购公司股份的进展公告。
Price History 价格走势
179 trading days 个交易日 · High 最高 ¥135.00 · Low 最低 ¥35.30The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
No broker has changed its rating on this company in the reports held.
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 华鑫证券 | 胡博新 | Buy 买入 | 23 Sep 2026 | 1 | — |
| 东海证券 | 杜永宏 | Buy 买入 | 22 Sep 2026 | 2 | — |
| 信达证券 | 唐爱金,章钟涛 | Unrated | 27 Apr 2026 | 1 | — |
| 国信证券 | 马千里,陈曦炳,彭思宇 | Outperform 增持 | 22 Apr 2026 | 2 | — |
| 太平洋 | 周豫,张崴 | Buy 买入 | 31 Dec 2025 | 1 | 74.25 |
Each row is a broker's latest report in the last twelve months. A price target is given in 1 of 7 reports. 每行为该券商近十二个月的最新研报；7 份中 1 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。